CN104292177B - 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途 - Google Patents
含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途 Download PDFInfo
- Publication number
- CN104292177B CN104292177B CN201410526293.7A CN201410526293A CN104292177B CN 104292177 B CN104292177 B CN 104292177B CN 201410526293 A CN201410526293 A CN 201410526293A CN 104292177 B CN104292177 B CN 104292177B
- Authority
- CN
- China
- Prior art keywords
- compound
- present
- base
- preparation
- halobenzene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- JUNAPQMUUHSYOV-UHFFFAOYSA-N 2-(2h-tetrazol-5-yl)acetic acid Chemical class OC(=O)CC=1N=NNN=1 JUNAPQMUUHSYOV-UHFFFAOYSA-N 0.000 title abstract description 5
- 150000005171 halobenzenes Chemical group 0.000 title abstract description 5
- 125000002560 nitrile group Chemical group 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 12
- 201000005569 Gout Diseases 0.000 claims abstract description 11
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 40
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 5
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 2
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 claims description 2
- -1 compound 2-halogenated acetic acids Chemical class 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 9
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 9
- 229940116269 uric acid Drugs 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 239000003112 inhibitor Substances 0.000 abstract description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 0 *C[n]1nnc(CCCN(c2ccccc2)c(cc2)c(cccc3)c3c2C#N)n1 Chemical compound *C[n]1nnc(CCCN(c2ccccc2)c(cc2)c(cccc3)c3c2C#N)n1 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- FGQFOYHRJSUHMR-UHFFFAOYSA-N lesinurad Chemical compound OC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 FGQFOYHRJSUHMR-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- ASUMVAPLXCRBMA-UHFFFAOYSA-N (3,5-dichloro-4-hydroxyphenyl)-(2,3-dihydro-1,4-benzoxazin-4-yl)methanone Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1C(=O)N1C2=CC=CC=C2OCC1 ASUMVAPLXCRBMA-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241001415342 Ardea Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102100030935 Solute carrier family 2, facilitated glucose transporter member 9 Human genes 0.000 description 2
- 229940083914 URAT1 inhibitor Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960003838 lesinurad Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- YLWAQARRNQVEHD-PBZHRCKQSA-N tazettine Chemical compound O([C@]1(O)CN2C)CC3=CC=4OCOC=4C=C3[C@]31[C@@H]2C[C@H](OC)C=C3 YLWAQARRNQVEHD-PBZHRCKQSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108010078530 urate transporter Proteins 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010068701 Pegloticase Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- XEEPVFFWNATEGX-IUHNQTRMSA-N Tazettadiol Natural products C1=C(CO)C([C@]23[C@H](O)CN(C)[C@H]2C[C@@H](C=C3)OC)=CC2=C1OCO2 XEEPVFFWNATEGX-IUHNQTRMSA-N 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- IDAGXRIGDWCIET-SDFKWCIISA-L disodium;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxyhexanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IDAGXRIGDWCIET-SDFKWCIISA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical class [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229960001376 pegloticase Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- ZVIWEYTXPYNLGB-UHFFFAOYSA-M potassium;4-[[2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetyl]amino]-3-chlorobenzoate Chemical compound [K+].ClC1=CC(C(=O)[O-])=CC=C1NC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 ZVIWEYTXPYNLGB-UHFFFAOYSA-M 0.000 description 1
- KLJOYDMUWKSYBP-SLEMLFNQSA-N pretazettine Natural products CO[C@H]1C[C@@H]2N(C)C[C@@H]3O[C@@H](O)c4cc5OCOc5cc4[C@]23C=C1 KLJOYDMUWKSYBP-SLEMLFNQSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- YLWAQARRNQVEHD-UHFFFAOYSA-N sekisanoline Natural products CN1CC2(O)OCC3=CC=4OCOC=4C=C3C32C1CC(OC)C=C3 YLWAQARRNQVEHD-UHFFFAOYSA-N 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及与高尿酸血症和痛风相关的药物领域。具体而言，本发明涉及一类含腈基和卤苯取代的四氮唑乙酸结构的尿酸转运体1抑制剂、其制备方法、及含有它们的药物组合物以及它们在制备糖尿病药物中的应用。
Description
技术领域
本发明涉及治疗高尿酸血症和痛风相关的药物领域。具体而言，本发明涉及对高尿酸血症和痛风有治疗作用的一类含腈基和卤苯取代的四氮唑乙酸结构的尿酸转运体1(urate transporter 1,URAT1)抑制剂、制备方法、含有它们的药物组合物以及在医药上的用途。
背景技术
痛风是一种慢性代谢性疾病，以高尿酸血症和尿酸单钠盐(MSU)沉积在关节等部位而引起的痛疼为主要特征，主要原因为嘌呤代谢紊乱和/或尿酸排泄障碍。据估计，目前全球痛风患者有2000多万。目前用于治疗痛风的药物包括用于缓解疼痛的抗炎药物(如秋水仙碱等)、抑制尿酸生成药物(以别嘌醇和非布索坦为代表的黄嘌呤氧化酶抑制剂)、粗尿酸排泄药物(以丙磺舒、苯磺唑酮、苯溴马隆和氯沙坦为代表的尿酸排泄药物)和尿酸酶(以pegloticase为代表)。这些药物存在不同的程度的毒副作用，如苯溴马隆有引起爆发性肝炎的危险，别嘌醇有肝脏及骨髓毒性和变态反应等不良反应，等等。
Lesinurad(RDEA 594)是一种由Ardea公司研制的可以抑制肾脏中尿酸转运体(urate transporter 1,URAT1)而通过尿液的途径来排出血液中尿酸的口服药物，目前处于III期临床阶段。Lesinurad最早由Valeant公司研发的抗病毒药物RDEA806发展而来。现在Lesinurad的所有权目前由于Ardea公司被收购而属于Astra Zeneca。
本发明公开了一类含腈基和卤苯取代的四氮唑乙酸结构的URAT1抑制剂，这些化合物可用于制备治疗高尿酸血症和痛风的药物。
发明内容
本发明的一个目的是提供一种具有良好活性，具有通式I的一类化合物。
本发明的另一个目的是提供制备具有通式I的化合物的方法。
本发明的再一个目的是提供含有通式I的化合物作为有效成分，以及一种或多种药学上可接受的载体、赋形剂或稀释剂的药用组合物，及其在治疗痛风方面的应用。
现结合本发明的目的对本发明内容进行具体描述。
本发明具有通式(I)的化合物具有下述结构式：
其中，X选自卤素取代基。
优选以下通式(I)化合物，
进一步，优选以下通式(I)化合物，
本发明所述通式(I)化合物通过以下路线合成：
化合物II用与4-卤代丁腈III在碱存在下反应，得到化合物IV；化合物IV在碱存在下与二卤代苯C6H4X2(V)反应得到化合物VI；化合物VI与NaN3在NH4Cl存在下反应，得到产物VII；VII与化合物2-卤代乙酸VIII在碱存在下反应得到产物I；X选自Cl、Br和I，所述碱选自有机碱、无机碱，X定义对应如权利要求1-3所述。
本发明所述通式I化合物具有URAT1的抑制作用，可作为有效成分用于制备高尿酸血症和痛风的治疗药物。本发明所述通式I化合物的活性是通过受体结合试验来验证的。
本发明的通式I化合物在相当宽的剂量范围内是有效的。例如每天服用的剂量约在1mg-500mg/人范围内，分为一次或数次给药。实际服用本发明通式I化合物的剂量可由医生根据有关的情况来决定。
具体实施方式
下面结合实施例对本发明作进一步的说明。需要说明的是，下述实施例仅是用于说明，而并非用于限制本发明。本领域技术人员根据本发明的教导所做出的各种变化均应在本申请权利要求所要求的保护范围之内。
实施例1化合物I-1的合成
A.化合物IV-1的合成
3.36g(20mmol)化合物II-1和2.96g(20mmol)化合物III-1溶于40mL干燥的DMF中，搅拌，加入3.32g(20mmol)碘化钾和6.91g(50mmol)碳酸钾，在氮气气氛中100℃下反应，直到反应完成(TLC跟踪，一般5h)。反应混合物冷却后，倾倒入300mL冰水中，搅拌，使用100mL×3的CH2Cl2萃取，合并萃取相，使用100mL 5％的盐水洗涤，无水硫酸钠干燥。抽滤除去干燥剂，滤液在旋转蒸发仪上蒸干，得到的残余物使用柱层析纯化，得到化合物IV-1，白色固体，ESI-MS,m/z＝258([M+Na]+)。
B.化合物VI-1的合成
2.82g(12mmol)化合物IV-1和1.76g(12mmol)间二氯甲苯V-1溶于30mL干燥的DMF中，搅拌，加入4.98g(36mmol)碳酸钾，在氮气气氛中100℃下反应，直到反应完成。反应混合物冷却后，倾倒入300mL冰水中，搅拌，使用100mL×3的CH2Cl2萃取，合并萃取相，使用100mL5％的盐水洗涤，无水硫酸钠干燥。抽滤除去干燥剂，滤液在旋转蒸发仪上蒸干，得到的残余物使用柱层析纯化，得到化合物VI-1，白色固体，ESI-MS,m/z＝368([M+Na]+)。
C.化合物VII-1的合成
3.01g(8mmol)化合物VI-1溶于20mL干燥的DMF中，搅拌，加入1.30g(20mmol)NaN3和1.07g(20mmol)氯化铵，而后在氮气气氛中120℃下反应，直到反应完成。反应混合物冷却后，倾倒入200mL冰水中，搅拌，使用100mL×3的CH2Cl2萃取，合并萃取相，使用100mL 5％的盐水洗涤，无水硫酸钠干燥。抽滤除去干燥剂，滤液在旋转蒸发仪上蒸干，得到的残余物使用柱层析纯化，得到化合物VII-1，白色固体，ESI-MS,m/z＝411([M+Na]+)。
D.化合物I-1的合成
1.94g(5mmol)化合物VII-1和1.39g(10mmol)溴乙酸溶于15mL乙醇中，室温下搅拌，慢慢滴加含有1.20g(30mmol)NaOH的3mL水溶液，所得混合物升温至50℃加热，直到反应完成。反应混合物冷却后，倾倒入100mL冰水中，搅拌，浓盐酸调节pH＝2-3，使用50mL×3的CH2Cl2萃取，合并萃取相，使用100mL 5％的盐水洗涤，无水硫酸钠干燥。抽滤除去干燥剂，滤液在旋转蒸发仪上蒸干，得到的残余物使用柱层析纯化，得到化合物IV-1，白色固体，ESI-MS,m/z＝445([M-H]-)。
实施例2-10
参照实施例1操作步骤，制备了下表所列化合物。
实施例11
本发明所述的化合物及相关化合物对URAT1抑制的IC50值按照文献记载的类似的方法测定(US2014/0005136中实施例12)。
构建稳定表达人源化URAT1转运体的细胞株：将人源化URAT1基因(SLC22A112)从质粒pCMV6-XL-5(Origene)亚克隆到真核表达的质粒pCMV6/neo(Origene)上。基因测序证实了人源化URAT1与基因库中记录的信息一致(NM_144585.2)。HEK293人胚胎肾细胞(ATCC#CRL-1573)在EMEM组织培养液中在5％的CO2和95％的空气气氛中培养。使用L2000型转染剂(Invitrogene)将pCMV6/Neo/URAT1转染到HEK293细胞上。24小时后，将被转染的细胞分到直径为10cm的组织培养皿中，继续生长一天，而后将培养基更换为含有0.5mg/mL G418(Gibco)的新鲜的培养基。8天后，选择并收集耐药性菌落，并用其测试对14C-标记的尿酸的转运活性。将HEK293/URAT1细胞以75,000/孔的密度种植于聚D-赖氨酸覆盖的96孔板上。
这些细胞在培养箱中37℃下生长过夜，而后冷却到室温下，其中的培养液使用250μL/孔的清洗液洗涤一次(125mM葡萄糖酸钠、pH＝7.3的10m MHEPES)。将待测化合物或者空白对照加到含有40μM的14C-标记尿酸(54mCi/mmol)的缓冲液中，所述缓冲液含有125mM葡萄糖酸钠、4.8mM葡萄糖酸钾、1.2mM磷酸二氢钾、1.2mM硫酸镁、1.3mM葡萄糖酸钙、5.6mM葡萄糖、25mM HEPES，最终pH＝7.3。96孔板在室温下培养10分钟，接着依次用50μL/孔和250μL/孔的上述清洗液各清洗三次。在96孔板上加入Microscint 20型液闪剂，板子在45℃下培养过夜，而后在TopCount Plate Reader上读数，并据此计算IC50。
结果如下列表所示。
本发明的部分化合物对URAT1的IC50值
上述IC50的测定结果表明，本发明的化合物为强的URAT1抑制剂，可以用来制备治疗高尿酸血症和痛风的药物。
Claims (5)
1.具有通式I结构的化合物，
其中，X选自卤素取代基。
2.下列化合物：
3.权利要求2所述化合物，选自：
4.合成权利要求1所定义的通式I的化合物的方法：
化合物II用与4-卤代丁腈III在碱存在下反应，得到化合物IV；化合物IV在碱存在下与二卤代苯C6H4X2(V)反应得到化合物VI；化合物VI与NaN3在NH4Cl存在下反应，得到产物VII；VII与化合物2-卤代乙酸VIII在碱存在下反应得到产物I；所述碱选自有机碱、无机碱，X定义对应如权利要求1所述。
5.权利要求1-3任一所定义的化合物在制备治疗高尿酸血症和痛风药物方面的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410526293.7A CN104292177B (zh) | 2014-10-07 | 2014-10-07 | 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410526293.7A CN104292177B (zh) | 2014-10-07 | 2014-10-07 | 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104292177A CN104292177A (zh) | 2015-01-21 |
| CN104292177B true CN104292177B (zh) | 2016-08-17 |
Family
ID=52312166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410526293.7A Active CN104292177B (zh) | 2014-10-07 | 2014-10-07 | 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104292177B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1356977A (zh) * | 1999-05-17 | 2002-07-03 | 诺沃挪第克公司 | 胰高血糖素拮抗剂/反向激动剂 |
| WO2008021804A2 (en) * | 2006-08-09 | 2008-02-21 | Allergan, Inc. | Therapeutic amides and related compounds |
| US20100056542A1 (en) * | 2008-09-04 | 2010-03-04 | Ardea Biosciences | Compounds, compositions and methods of using same for modulating uric acid levels |
| CN102014898A (zh) * | 2008-04-30 | 2011-04-13 | 维尔斯达医疗公司 | 用于减少尿酸的四唑化合物 |
-
2014
- 2014-10-07 CN CN201410526293.7A patent/CN104292177B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1356977A (zh) * | 1999-05-17 | 2002-07-03 | 诺沃挪第克公司 | 胰高血糖素拮抗剂/反向激动剂 |
| WO2008021804A2 (en) * | 2006-08-09 | 2008-02-21 | Allergan, Inc. | Therapeutic amides and related compounds |
| CN102014898A (zh) * | 2008-04-30 | 2011-04-13 | 维尔斯达医疗公司 | 用于减少尿酸的四唑化合物 |
| US20100056542A1 (en) * | 2008-09-04 | 2010-03-04 | Ardea Biosciences | Compounds, compositions and methods of using same for modulating uric acid levels |
| CN103819419A (zh) * | 2008-09-04 | 2014-05-28 | 亚德生化公司 | 调节尿酸含量的化合物、组合物及其使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104292177A (zh) | 2015-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104262277B (zh) | 含硝基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途 | |
| CN104311442B (zh) | 卤代萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
| CN104262276B (zh) | 含卤代苯的四氮唑乙酸类化合物、其制备方法及用途 | |
| CN104292178B (zh) | 含四氮唑乙酸类化合物、其制备方法及用途 | |
| CN104292177B (zh) | 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途 | |
| CN104341362B (zh) | 三氮唑磺酰丙二酸类化合物、其制备方法及用途 | |
| CN104370841B (zh) | 三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 | |
| CN104292176B (zh) | 一种含卤代苯的四氮唑乙酸类化合物、其制备方法和用途 | |
| CN104292123B (zh) | 苯基萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
| CN104292175B (zh) | 含硝基的四氮唑乙酸类化合物、其制备方法及用途 | |
| CN104341367B (zh) | 一类四氮唑乙酸类化合物、其制备方法及用途 | |
| CN104230833B (zh) | 含腈基的四氮唑乙酸类化合物、其制备方法及用途 | |
| CN104341361B (zh) | 一种腈基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 | |
| CN104326993B (zh) | 一种硝基取代三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 | |
| CN104326999B (zh) | 烷氧基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 | |
| CN104326997B (zh) | 烷氧基取代的三氮唑丙二酸类化合物、其制备方法及用途 | |
| CN104326998B (zh) | 苯基取代的三氮唑丙二酸类化合物、其制备方法及用途 | |
| CN104370842B (zh) | 苯基取代的三氮唑磺酰丙二酸类化合物、其制备方法及用途 | |
| CN104327000B (zh) | 苯基取代的三氮唑亚磺酰丙二酸类化合物、其制备方法及用途 | |
| CN104311443B (zh) | 一类含萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
| CN104193644B (zh) | 甲氧萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
| CN104341364A (zh) | 三氮唑丙二酸类化合物、其制备方法及用途 | |
| CN104311452B (zh) | 腈基萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
| CN104311441B (zh) | 一类氯代萘环的丁二酸酰胺衍生物、其制备方法及用途 | |
| CN104292124B (zh) | 硝基苯基取代的萘环丁二酸酰胺衍生物、其制备方法及用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181220 Address after: 408300 Tongji Village, Chengxi Town, Dinjiang County, Chongqing Patentee after: Chongqing Xingfa Jinguan Chemical Co. Ltd. Address before: 528000 floor 5, Pu Lan Road, Chancheng District, Foshan, Guangdong. Patentee before: Zhang Yuanqiang |
|
| TR01 | Transfer of patent right |